Target RWE and NoviSci Rebrand as Pedestal Health and Headwater Science
Target RWE and NoviSci Rebrand as Pedestal Health and Headwater Science Target RWE and NoviSci have announced a major rebranding initiative as the two organizations position themselves to reshape how…
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Hypertension Adults
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment…
Gossamer Bio Reports First Quarter 2026 Financial Results and Operational Highlights
Gossamer Bio Reports Q1 2026 Financial Results and Highlights Recent Business Progress Gossamer Bio has reported its financial results for the first quarter ended March 31, 2026, while also providing…
Parabilis Medicines and Regeneron Pharmaceuticals Partner to Develop Novel Antibody-Helicon™ Conjugates
Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a…
Agenus Publishes Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Liver Cancer
Agenus Publishes Promising Phase 1b Data for Botensilimab and Balstilimab Combination in Advanced Liver Cancer Agenus has announced the publication of new clinical data highlighting the potential of its investigational…
Lantern Pharma Announces First Quarter 2026 Financial Results and Corporate Updates
Lantern Pharma Reports First Quarter 2026 Results While Expanding AI-Driven Oncology and Commercial AI Platform Strategy Lantern Pharma reported operational highlights and financial results for the first quarter ended March…
Genentech Wins FDA Approval for Tecentriq in ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer
Genentech Receives FDA Approval for Tecentriq in ctDNA-Guided Treatment of Muscle-Invasive Bladder Cancer Genentech announced that the U.S. Food and Drug Administration has approved both Tecentriq and Tecentriq Hybreza as…
Signatera CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer
Natera Receives FDA Approval for Signatera CDx as First Blood-Based MRD Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera announced that the U.S. Food and Drug Administration has approved Signatera CDx…
Amylyx Pharmaceuticals Publishes Phase 2 HELIOS Trial Data for AMX0035 in JCI
Amylyx Publishes Phase 2 HELIOS Trial Results Showing Continued Benefits of AMX0035 in Wolfram Syndrome Amylyx Pharmaceuticals announced that detailed Week 24 and Week 48 findings from the Phase 2…
ICUS Applauds New Proposal Advancing CEUS Training for Sonographers
ICUS Supports New Sonography Training Standards Expanding Education in Contrast Enhanced Ultrasound International Contrast Ultrasound Society has expressed strong support for newly proposed accreditation standards that could significantly expand education…
Bayer Launches Midol® in Motion Campaign to Promote PMS Relief Through Physical Activity
Bayer Launches Midol in Motion Campaign to Support PMS Symptom Relief Through Movement and Education Bayer has announced the launch of “Midol in Motion,” a new awareness and education campaign…
Enveric Biosciences Announces First Quarter 2026 Financial Results and Business Update
Enveric Biosciences Reports First Quarter 2026 Results and Advances Non-Hallucinogenic Neuroplastogen Pipeline Enveric Biosciences reported financial results for the first quarter ended March 31, 2026, while also providing an extensive…